Skip to main content
. 2020 Nov 6;18(11):e3000970. doi: 10.1371/journal.pbio.3000970

Fig 1. Overall workflow of this study.

Fig 1

(A) A diagram illustrating the basic pathogenesis of SARS-CoV-2. (B) A diagram illustrating how to build a global interactome map for SARS-CoV-2. We compiled the SARS-CoV-2 human target gene/protein sets from multi-omics data from the transcriptome, proteome, and human interactome, and validated network-based findings using patient data from a COVID-19 registry. (C) A diagram illustrating network-based measurement of disease manifestations associated with COVID-19. We systematically evaluated the network proximities of the SARS-CoV-2 human target genes/proteins with 64 diseases across 6 main categories: autoimmune, cancer, cardiovascular, metabolic, neurological, and pulmonary. (D) A workflow illustrating validation of network-based findings. We performed single-cell analyses to further investigate the underlying mechanisms of COVID-19 with asthma and inflammatory bowel disease. We prioritized nearly 3,000 US Food and Drug Administration–approved/investigational drugs for their potential anti-SARS-CoV-2 effects from network-based findings and validated drug–COVID-19 outcomes using an institutional review board–approved COVID-19 patient registry.